Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423184 | 0.94 | GSK3B (0.50) | GSK3BCYP1A2CYP2D6GAAPIK3R1 | |
| SCHEMBL4423179 | 0.94 | GSK3B (0.50) | GSK3BCYP1A2CYP2D6GAAPIK3R1 | |
| SCHEMBL3365321 | 0.94 | GSK3B (0.50) | GSK3BCYP1A2CYP2D6PIK3R1PIK3CA | |
| SCHEMBL3366954 | 0.92 | GSK3B (0.48) | GSK3BCYP1A2CYP2D6PIK3R1PIK3CA | |
| SCHEMBL3364502 | 0.92 | GSK3B (0.48) | GSK3BCYP1A2CYP2D6PIK3R1PIK3CA | |
| SCHEMBL3366917 | 0.92 | GSK3B (0.48) | GSK3BCYP1A2CYP2D6PIK3R1PIK3CA | |
| SCHEMBL3366822 | 0.92 | GSK3B (0.48) | GSK3BCYP1A2CYP2D6PIK3R1PIK3CA | |
| SCHEMBL5554356 | 0.90 | GSK3B (0.46) | GSK3BCYP1A2CYP2D6PIK3R1PIK3CA | |
| SCHEMBL5554351 | 0.90 | GSK3B (0.46) | GSK3BCYP1A2CYP2D6PIK3R1PIK3CA | |
| SCHEMBL4871119 | 0.88 | GSK3B (0.51) | GSK3BCYP1A2CYP2D6PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081820-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | US | claimed |
| EP-1699795-B1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKLYMINE]-PYRIMIDO[1,2A]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2007-04-25 | — | — | EP | claimed |
| EP-1557417-B1 | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives | SANOFI AVENTIS (FR) | 2007-03-07 | — | — | EP | claimed |
| EP-1557417-A1 | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2a] pyrimidin-6-one derivatives | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | claimed |
| US-7547705-B2 | Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| US-20080081820-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | US | disclosed |
| EP-1572203-B1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | EP | disclosed |
| EP-1699795-B1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKLYMINE]-PYRIMIDO[1,2A]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2007-04-25 | — | — | EP | disclosed |
| EP-1557417-B1 | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives | SANOFI AVENTIS (FR) | 2007-03-07 | — | — | EP | disclosed |
| US-7109225-B2 | Antidiabetic agents; hypotensive agents; anticholesterol agents; antilipemic agents; antiinflammatory agents; antiproliferative agents | HOFMANN-LA ROCHE INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1557417-A1 | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2a] pyrimidin-6-one derivatives | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
| US-20040157898-A1 | Novel substituted oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157898-A1 | Novel substituted oxazole derivatives | OXA1L, SLC5A1, GPR119 | GSK3B 687/4885CYP1A2 112/4885CYP2D6 103/4885 |
| US-20080081820-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | GSK3B 1/4885CYP1A2 1683/4885CYP2D6 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.